News

Alniche Life Sciences wins award at CPHI – India Pharma Awards 2019

New Delhi, November 26, 2019 – Alniche Life Sciences, a specialty healthcare company, has won New Product Launch Award for CompliPro under the category of Excellence in Pharmaceutical Brand Management. In this category, another brand Ketoalfa was one among top brands nominated. This prestigious pharma award was presented by Executive Vice President, Informa Markets Asia, Mr. Michael Duck at New Delhi India. 

Standing (L-R) – Mr. Arvind Kumar (Marketing Manager Alniche Life Sciences), Mr. Michael Duck (Executive Vice President, Informa Markets Asia), Mr. Karan Arora (Director International Business Alniche Life Sciences), Mr. Vijay Chauhan (Head-BD Alniche Life Sciences) and Ms. Insha Khan (Manager- International Marketing & Corporate Affairs Alniche Life Sciences).

CPhI- India Pharma Awards are one of the most admired recognitions in the Pharmaceutical industry. This year’s awards included 12 categories that span the entire industry to recognize their innovations, technologies and strategies.

Alniche in collaboration with DPSRU (Delhi Pharmaceutical Science and Research University) has developed CompliPro, the first ready-to-use Right-Quantity & High-Quality Protein Oral Supplement to compensate protein losses during dialysis. The product distinguishes itself from existing options of Protein powders by offering Ease of intake, No hassle of reconstitution and Easy on gut (no heaviness or flatulence). 

 “This award marks a momentous milestone for Alniche and signifies the beginning of Indian Pharma industry focusing on academia – industry collaboration and introducing products that are suited for Indian masses” shared Mr. Girish Arora, Founder & MD Alniche Life Sciences. He further added, “we are delighted that CompliPro is recognized by the Pharma industry which reinforces Alniche mission “Inspired by value, Driven by vision”.

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Related Articles

Leave a Reply

Back to top button
Close
Close